AbbVie Focuses On Humira’s Formulary Positioning Ahead Of Biosimilars

 
• By Joseph Haas

A year out from the US patent expiration for top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain until 2024.

AbbVie exterior
AbbVie talked about US formulary positioning for Humira post-patent expiry • Source: Alamy

More from Earnings

More from Business